Research

Research excellence at the University of Kent


 

Biosciences contract research start-up acquired by major European company

Successful biotech start-up Cangenix – which is based at the University’s School of Biosciences – has been acquired by Argenta, part of Galapagos NV’s service division, one of Europe’s largest contract research organisations.

Cangenix was launched 15 months ago when Professor David Brown, formerly of Pfizer, was appointed chair of Structural Biology at the University. It offers crystallography – a structure-based drug design tool – and biophysics services to the pharmaceutical and biotech industry. Bioscience research students also benefit from the company’s cutting edge expertise.

Professor Brown said: ‘I’m hoping there will be opportunities to forge even stronger links between the University and Argenta in the Drug Discovery area.

'Cangenix will continue to operate at the School of Biosciences premises, offering structure based drug design contract research through Argenta. But I’m hoping also that we will be able to widen links beyond Biosciences to other areas of synergy within the University.'



Contact: M.J.Herrema@kent.ac.uk

Story published at 12:15pm 4 February 2013

Follow us on Twitter

For all the latest press releases and research stories

Find out who else to follow by looking at @UniKent's lists

Twitter

Find an expert

For research collaborators, media commentators or a research supervisor, try our research expertise search:

Academic staff profiles

 


Corporate Communications

The University of Kent, Canterbury, Kent, CT2 7NZ, T: +44 1227 764000

Last Updated: 09/05/2013